Not so fast , says Gerald Gartlehner , M . D . , M . P . H . , who coauthored a review of the benefits and risks of the same 12 drugs published last November in the Annals of Internal Medicine . He and his colleagues concluded , based on their review done while Gartlehner was at the RTI UNC Evidence Based Practice Center in Chapel Hill , North Carolina . , that there was no clinically meaningful evidence that any one of the drugs was better than the rest . Instead , they argued , decisions on which drug to use should be based on factors such as cost and side effects .
